A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL).
- Fleming, Shaun Alan, (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research